Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5137-5149

  Chen, Jyh Ping ^a   Yang, Pei Ching ^a   Ma, Yunn Hwa ^a   Tu, Su Ju ^a   Lu, Yu Jen ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Drug delivery; Magnetic nanoparticles; Silica; Thrombolysis; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; LACTATE DEHYDROGENASE; MAGNETIC NANOPARTICLE; SILICON DIOXIDE; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BINDING AFFINITY; BINDING SITE; BIOCOMPATIBILITY; BLOOD CLOT LYSIS; BLOOD COMPONENT; BLOOD SAMPLING; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG STABILITY; ENZYME IMMOBILIZATION; ENZYME RELEASE; FEASIBILITY STUDY; FIBRINOLYSIS; IN VITRO STUDY; MICRO-COMPUTED TOMOGRAPHY; SURFACE PROPERTY;

BLOOD COAGULATION; FIBRINOLYTIC AGENTS; HUMANS; MAGNETITE NANOPARTICLES; MATERIALS TESTING; NANOCAPSULES; PROTEIN BINDING; SILICON DIOXIDE; TISSUE PLASMINOGEN ACTIVATOR;

MUS;

EID: 84870310787     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S36197     Document Type: Article

References (57)

1. Pankhurst QA, Connolly J, Jones SK, Dobson J. Applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys. 2003;36:R167-R181.
2. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26:3995-4021.
3. Sun C, Lee JSH, Zhang MQ. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008;60:1252-1265.
4. Figuerolaa A, Di Coratob R, Mannaa L, Pellegrinoa T. From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications. Pharmacol Res. 2010;62:126-143.
5. Gan SY, Chow M. Carboxyl group (-CO2H) functionalized ferromagnetic iron oxide nanoparticles for potential bio-applications. J Mater Chem. 2004;14:2781-2786.
6. Sun S, Ma M, Qiu N, et al. Affinity adsorption and separation behaviors of avidin on biofunctional magnetic nanoparticles binding to iminobiotin. Colloid Surface B. 2011;88:246-253.
7. Kaushik A, Khan R, Solanki PR, et al. Iron oxide nanoparticles-chitosan composite based glucose biosensor. Biosens Bioelectron. 2008;24: 676-683.
8. Sun J, Zhou SB, Hou P, et al. Synthesis and characterization of biocompatible Fe3O4 nanoparticles. J Biomed Mater Res. 2006;80A: 333-341.
9. Butterworth MD, Illum L, Davis SS. Preparation of ultrafine silica-and PEG-coated magnetite particles. Colloid Surface B. 2001;179: 93-102.
10. Fang C, Zhang M. Multifunctional magnetic nanoparticles for medical imaging applications. J Mater Chem. 2009;19:6258-6266.
11. Kohler N, Fryxell GE, Zhang M. A bifunctional poly(ethylene glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. J Am Chem Soc. 2004;126:7206-7011.
12. Barbe C, Bartlett J, Kong L, Finnie K, Lin HQ, Larkin M, etal. Silica particles: a novel drug-delivery system. Adv Mater. 2004;16: 1959-1966.
13. Jain TK, Roy I, De TK, Maitra AN. Nanometer silica particles encapsulating active compounds: A novel ceramic drug carrier. J Am Chem Soc. 1998;120:11092-11095.
14. Chen FH, Gao Q, Ni JZ. The grafting and release behavior of doxorubincin from Fe3O4@SiO2 core-shell structure nanoparticles via an acid cleaving amide bond: the potential for magnetic targeting drug delivery. Nanotechnology. 2008;19:165103.
15. Arruebo M, Galán M, Navascués N, etal. Development of magnetic nanostructured silica-based materials as potential vectors for drug-delivery applications. Chem Mater. 2006;18:1911-1919.
16. Zhou L, Wu W, Caruntu D, etal. Synthesis of porous magnetic hollow silica nanospheres for nanomedicine application. J Phys Chem C. 2007; 111:17473-17477.
17. Santra S, Tapec R, Theodoropoulou N, Dobson J, Hebard A, Tan WH. Synthesis and characterization of silica-coated iron oxide nanoparticles in microemulsion: the effect of nonionic surfactants. Langmuir. 2001;17:2900-2906.
18. Yi DK, Selvan ST, Lee SS, Papaefthymiou GC, Kundaliya D, Ying JY. Silica-coated nanocomposites of magnetic nanoparticles and quantum dots. J Am Chem Soc. 2005;127:4990-4991.
19. Li C, Ma C, Wang F, etal. Preparation and biomedical applications of core-shell silica/magnetic nanoparticle composites. J Nanosci Nanotechnol. 2012;12:2964-2972.
20. Yang CQ, Wang G, Lu ZY, Sun J, Zhuang JQ, Yang WS. Effect of ultrasonic treatment on dispersibility of Fe3O4 nanoparticles and synthesis of multi-core Fe3O4/SiO2 core/shell nanoparticles. J Mater Chem. 2005;15:4252-4257.
21. Lu ZY, Wang G, Zhuang JQ, Yang WS. Effects of the concentration of tetramethylammonium hydroxide peptizer on the synthesis of Fe3O4/SiO2 core/shell nanoparticles. Colloid Surface A. 2006;278:140-143.
22. Segal JB, Eng J, Tamariz LJ, Bass EB. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med. 2007;5:63-73.
23. Løvlien M, Johansson I, Hole T, Schei B. Early warning signs of an acute myocardial infarction and their influence on symptoms during the acute phase with comparisons by gender. Gend Med. 2009;6:444-453.
24. Anderson HV, Willerson JT. Thrombolysis in acute myocardial infarction. New Engl J Med. 1993;329:703-709.
25. van der Worp HB, van Gijn J. Clinical practice: acute ischemic stroke. New Eng J Med. 2007;357:572-579.
26. Bennett W, Paoni N, Keyt B, etal. High resolution analysis of functional determination of human tissue-type plasminogen activator. J Biol Chem. 1991;266:5191-5520.
27. Berger H, Pizzo S. Preparation of polyethylene glycol-tissue plasminogen activator adducts that retain functional activity: characteristics and behavior in three animal species. Blood. 1988;71:1641-1647.
28. Stricker RB, Wong D, Shiu DT, Reyes PT, Shuman MA. Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation. Blood. 1986;68:275-280.
29. Xie Y, Kaminski MD, Torno MD, Finck MR, Liu X, Rosengart AJ. Physicochemical characteristics of magnetic microspheres containing tissue plasminogen activator. J Magn Magn Mater. 2007;311:376-378.
30. Kaminski MD, Xie Y, Mertz CJ, Finck MR, Chen H, Rosengart AJ. Encapsulation and release of plasminogen activator from biodegradable magnetic microcarriers. Eur J Pharm Sci. 2008;35:96-103.
31. Ma YH, Wu SY, Wu T, Chang YJ, Hua MY, Chen JP. Magnetically targeted thrombolysis with recombinant tissue plasminogen activator bound to polyacrylic acid. Biomaterials. 2009;30:343-351.
32. Wu T, Hua MY, Chen JP, Wei KC, Jung SM, Chang YJ. Effects of external magnetic field on biodistribution of nanoparticles: a histological study. J Magn Magn Mater. 2007;311:372-375.
33. Janolino VJ, Swaisgood HE. A spectrophotometric assay for solid phase primary amino groups. Appl Biochem Biotechnol. 1992;36:81-85.
34. Liang JF, Song H, Li YT, Yang VC. A novel heparin/protamine-based pro-drug type delivery system for protease drugs. J Pharma Sci. 2000;89:664-673.
35. Berny MA, Patel IA, White-Adams TC, etal. Rational design of an ex vivo model of thrombosis. Cell Mol Bioeng. 2010;3:187-189.
36. Stöber W, Fink A, Bohn E. Controlled growth of monodisperse silica spheres in the micron size range. J Colloid Interf Sci. 1968;26:62-69.
37. Philipse AP, Van Bruggen MPB, Pathmamanoharan C. Magnetic silica dispersions: preparation and stability of surface-modified silica particles with a magnetic core. Langmuir. 1994;10:92-99.
38. Panella B, Vargas A, Ferri D, Baiker A. Chemical availability and reactivity of functional groups grafted to magnetic nanoparticles monitored in situ by ATR-IR spectroscopy. Chem Mater. 2009;21:4316-4322.
39. Hammond C. The Basics Of Crystallography and Diffraction. Oxford, UK: Oxford University Press; 1997.
40. Girgis E, Wahsh MMS, Othman AGM, Bandhu L, Rao KV. Synthesis, magnetic and optical properties of core/shell Co1-xZnxFe2O4/SiO2 nanoparticles. Nanoscale Res Lett. 2011;6:460.
41. Torno MD, Kaminski MD, Xie Y, etal. Improvement of in vitro thrombolysis employing magnetically-guided microspheres. Thrombosis Res. 2008;121:799-811.
42. Mahmoudi M, Sant S, Wang B, Laurent S, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev. 2011;63:24-46.
43. Koneracka M, Kopcansky P, Antalik M, Timko M, Ramchand CN, Lobo D. Immobilization of proteins and enzymes to fine magnetic particles. J Magn Magn Mater. 1999;201:427-430.
44. Goissis G, Marcantonio E Jr, Marcantonio RAC, Lia RCC, Cancian DCJ, De Carvalho WM. Biocompatibility studies of anionic collagen membranes with different degree of glutaraldehyde cross-linking. Biomaterials. 1999;20:27-34.
45. Trowbridge EA, Crofts CE. The extension rate independence of the hysteresis in glutaraldehyde-fixed bovine pericardium. Biomaterials. 1987;8:201-206.
46. Kempe H, Kempe M. The use of magnetite nanoparticles for implant-assisted magnetic drug targeting in thrombolytic therapy. Biomaterials. 2010;31:9499-9510.
47. Yoshioka S, Izutsu K, Aso Y, Takeda Y. Inactivation kinetics of enzyme pharmaceuticals in aqueous solution. Pharm Res. 1991;8:480-484.
48. Johnson PA, Park HJ, Driscoll AJ. Enzyme nanoparticle fabrication: magnetic nanoparticle synthesis and enzyme immobilization. Methods Mol Biol. 2011;679:183-191.
49. Hong J, Xu D, Gong P, Yu J, Ma H, Yao S. Covalent-bonded immobilization of enzyme on hydrophilic polymer covering magnetic nanogels. Microporous Mesoporous Mater. 2008;109:470-477.
50. Lee DG, Ponvel KM, Kim M, Hwang S, Ahn IS, Lee CH. Immobilization of lipase on hydrophobic nano-sized magnetite particles. J Mol Catal B Enzym. 2009;57:62-66.
51. Ganguly K, Krasik T, Medinilla S, etal. Blood clearance and activity of erythrocyte-coupled fibrinolytics. J Pharmacol Exp Ther. 2005;312: 1106-1113.
52. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb. 1989;9:87-115.
53. Ganguly K, Murciano JC, Westrick R, Leferovich J, Cines DB, Muzykantov VR. The glycocalyx protects erythrocyte-bound tissue-type plasminogen activator from enzymatic inhibition. J Pharmacol Exp Ther. 2007;321:158-164.
54. Madison EL, Goldsmith EJ, Gerard RD, Gething MJ, Sambrook JF, Bassel-Duby RS. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A. 1990;87:3530-3533.
55. Diamond SL. Engineering design of optimal strategies for blood clot dissolution. Annu Rev Biomed Eng. 1999;1:427-462.
56. Diamond SL, Anand S. Inner clot diffusion and permeation during fibrinolysis. Biophys J. 1993;65:2622-2643.
57. Pleydell CP, David T, Smye SW, Berridge DC. A mathematical model of post-canalization thrombolysis. Phys Med Biol. 2002;47:209-224.